Contract Services Methods Development
ProBioGen and the Berlin Institute of Health at Charité (BIH) announced that ProBioGen has been selected to operate the process...
September 17, 2025 | News
Bioprocess, Unbottled Single-use systems (SUS) have become a transformative force in biopharmaceutical processing, offering an alternative to trad...
September 16, 2025 | Report
Manufacturing excellence positions Seattle site as premier destination for mammalian and microbial biologic production in thriving Pacific Northwest life...
September 11, 2025 | News
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing organization (CDMO), and Infinimmune, Inc., a biotec...
September 09, 2025 | News
Highly Complementary Technologies Strengthen Thermo Fisher’s Portfolio in Bioprocessing and Adjacent Markets Thermo Fisher Scientific Inc. , the wor...
September 02, 2025 | News
The Phase I/II CLINCH study of ATG-022 (CLDN18.2 antibody-drug conjugate) demonstrated promising results, showing robust clinical efficacy and a fav...
August 25, 2025 | Company results
- Revenue increased by 62.2% YoY to RMB 2,701 million - Gross profit surged by 82.2% YoY to RMB 975 million, with i...
August 19, 2025 | Company results
Building on its success in developing continuous production at pilot-scale with the WuXiUP™ platform, WuXi Biologics has further enhanced the ...
August 13, 2025 | News
ProBio, a leading contract development and manufacturing organization (CDMO) specializing in gene and cell therapy, announced the launch of its cGMP Adeno-...
August 12, 2025 | News
PA5108, a new chemical entity, is an investigational, biodegradable ocular micro implant, designed to deliver sustained intraocular pressure control for ...
August 08, 2025 | News
AGC Biologics, your friendly CDMO expert, announced a development and manufacturing services agreement with specialty vaccine company Valneva SE ...
July 31, 2025 | News
Leading GMP cell CDMO I Peace, Inc. specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that the co...
July 11, 2025 | News
The WuXiHigh™2.0 technology platform harnesses proprietary excipient blends and expertise to enable concentrations up to 230 mg/mL It reduces visc...
July 01, 2025 | News
Production site expected to be fully operational by the end of 2029 Modern site with holistic approach for state-of-the-art manufacturing operations Fu...
June 30, 2025 | News
Most Read
Bio Jobs
News
Editor Picks